Atrial Fibrillation Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Bayer, Johnson and Johnson, Bristol Myers-Squibb, Daiichi Sankyo, Pfizer, Anthos Therapeuti

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atrial Fibrillation pipeline constitutes 15+ key companies continuously working towards developing 15+ Atrial Fibrillation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Atrial Fibrillation Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market.

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Atrial Fibrillation Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years.

*
Atrial Fibrillation companies working in the treatment market are Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others, are developing therapies for the Atrial Fibrillation treatment

*
Emerging Atrial Fibrillation therapies in the different phases of clinical trials are- Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.

*
In July 2025, DeepQure announced that South Korea's Ministry of Food and Drug Safety (MFDS) has granted approval for a clinical trial of its HyperQure Trademark RDM System, an innovative laparoscopic renal denervation (RDN) technology, for treating atrial fibrillation (AF). The study aims to assess the safety and effectiveness of laparoscopic RDN in patients with recurrent AF after pulmonary vein isolation (PVI) and those with resistant hypertension. Designed as a multicenter, prospective, single-arm, open-label exploratory trial, it will provide key insights into the potential of this novel approach.

*
In March 2025, At the American College of Cardiology's 74th Annual Scientific Session in Chicago, Fretz et al. presented findings from a study examining the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on atrial fibrillation (AF) occurrence after hospitalisation for heart failure (HF). The onset of AF in HF patients is linked to higher morbidity and mortality rates. While GLP-1RA therapies have been shown to lower cardiovascular (CV) risk and enhance outcomes in patients with preserved-ejection fraction HF, their influence on AF incidence in HF populations has not yet been fully established.

*
In January 2025, The initial phase of the ADVANTAGE AF clinical trial successfully met its safety and efficacy endpoints for treating drug-resistant, symptomatic, persistent atrial fibrillation using the FARAPULSE Trademark Pulsed Field Ablation System. Additionally, a sub-analysis from the OPTION clinical trial demonstrated consistent safety and effectiveness of the WATCHMAN FLX Trademark Left Atrial Appendage Closure Device when used after cardiac ablation, whether performed simultaneously (concomitant) or separately (sequential).

Atrial Fibrillation Overview

Atrial Fibrillation is an irregular or trembling heartbeat that raises the risk of blood clots, stroke, heart failure, and other issues related to the heart. The two upper chambers of the heart, known as the atria, beat erratically and chaotically during atrial fibrillation, not in time with the lower chambers, known as the ventricles.

Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight [https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:

*
Research programme: Thryv Therapeutics Inc.

*
CTP-Amio: Vivasc Therapeutics

*
VE 1902: Verseon

*
HBI-3000: HUYA Bioscience

*
HSY 244: Novartis

*
AGN-151607: AbbVie

*
Asundexian: Bayer AG

*
Inrhythm: InCarda Therapeutics, Inc.

Atrial Fibrillation Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Atrial Fibrillation Molecule Type

Atrial Fibrillation Products have been categorized under various Molecule types, such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Atrial Fibrillation Pipeline Therapeutics Assessment

*
Atrial Fibrillation Assessment by Product Type

*
Atrial Fibrillation By Stage and Product Type

*
Atrial Fibrillation Assessment by Route of Administration

*
Atrial Fibrillation By Stage and Route of Administration

*
Atrial Fibrillation Assessment by Molecule Type

*
Atrial Fibrillation by Stage and Molecule Type

DelveInsight's Atrial Fibrillation Report covers around 15+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Atrial Fibrillation Therapeutics Market include:

Key companies developing therapies for Atrial Fibrillation are - Bayer, Johnson and Johnson, Bristol Myers-Squibb, Daiichi Sankyo, Pfizer, Anthos Therapeutics, Cadrenal Therapeutics, Boehringer Ingelheim, InCarda Therapeutics, and others.

Atrial Fibrillation Pipeline Analysis:

The Atrial Fibrillation pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.

*
Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Atrial Fibrillation Pipeline Market Drivers

*
Rising prevalence of Atrial fibrillation, increase in the Adoption of Advanced Technologies are some of the important factors that are fueling the Atrial Fibrillation Market.

Atrial Fibrillation Pipeline Market Barriers

*
However, complications associated with the use of Atrial fibrillation drugs, lack of awareness regarding medical therapy in underdeveloped and developing regions and other factors are creating obstacles in the Atrial Fibrillation Market growth.

Scope of Atrial Fibrillation Pipeline Drug Insight

*
Coverage: Global

*
Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others

*
Key Atrial Fibrillation Therapies: Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others

*
Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies

*
Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers

Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Atrial Fibrillation Report Introduction

2. Atrial Fibrillation Executive Summary

3. Atrial Fibrillation Overview

4. Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment

5. Atrial Fibrillation Pipeline Therapeutics

6. Atrial Fibrillation Late Stage Products (Phase II/III)

7. Atrial Fibrillation Mid Stage Products (Phase II)

8. Atrial Fibrillation Early Stage Products (Phase I)

9. Atrial Fibrillation Preclinical Stage Products

10. Atrial Fibrillation Therapeutics Assessment

11. Atrial Fibrillation Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Atrial Fibrillation Key Companies

14. Atrial Fibrillation Key Products

15. Atrial Fibrillation Unmet Needs

16 . Atrial Fibrillation Market Drivers and Barriers

17. Atrial Fibrillation Future Perspectives and Conclusion

18. Atrial Fibrillation Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atrial-fibrillation-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-bayer-johnson-and-johnson-bristol-myerssquibb-daiichi-sankyo-pfizer-anthos-therapeuti]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.